Yang Hai, Li Jinping, Li Xiaoxiong, Ma Linqiu, Hou Mingliang, Zhou Huadong, Zhou Rui
Department of Neurology, Army Medical Center of PLA, Chongqing, China.
Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Front Mol Neurosci. 2022 Aug 31;15:927530. doi: 10.3389/fnmol.2022.927530. eCollection 2022.
Amyloid-β (Aβ) has long been considered as one of the most important pathogenic factors in Alzheimer's disease (AD), but the specific pathogenic mechanism of Aβ is still not completely understood. In recent years, the development of structural biology technology has led to new understandings about Aβ molecular structures, Aβ generation and clearance from the brain and peripheral tissues, and its pathological toxicity. The purpose of the review is to discuss Aβ metabolism and toxicity, and the therapeutic strategy of AD based on the latest progress in molecular structures of Aβ. The Aβ structure at the atomic level has been analyzed, which provides a new and refined perspective to comprehend the role of Aβ in AD and to formulate therapeutic strategies of AD.
淀粉样蛋白β(Aβ)长期以来一直被认为是阿尔茨海默病(AD)最重要的致病因素之一,但其具体致病机制仍未完全明确。近年来,结构生物学技术的发展使人们对Aβ分子结构、Aβ在脑和外周组织中的生成与清除及其病理毒性有了新的认识。本文综述旨在基于Aβ分子结构的最新进展,探讨Aβ代谢与毒性以及AD的治疗策略。对Aβ原子水平的结构进行了分析,这为理解Aβ在AD中的作用以及制定AD治疗策略提供了全新且精确的视角。